N/A N=4 Efficacy Study to Evaluate Laparoscopic Fascial Closure Device
Hernia, Abdominal
Primary: Count of Participants With Successful Port Site Closure Using Port Close Device — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=129 The SENTRY Clinical Study
Pulmonary Embolism · Deep Vein Thrombosis
Primary: Number of Subjects That Reported Clinical Success — 111 Participants
Phase 2 N=140 PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC0-12 — 1.448; 1.416; 1.432; 1.416 Liter
N/A N=41 Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Hodgkin Lymphoma, Adult
Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=16 Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
Lung Cancer · Precancerous Condition · Tobacco Use Disorder
Primary: Grade III-IV Toxicities or Any Grade II Toxicities Lasting More Than 2 Weeks — 1; 0; 0; 0 participants
Phase 3 N=438 OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants
Phase 3 N=48 Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
Thromboembolism
Primary: Rate of Major Bleeding During Treatment Period — 21.6 % of normalized events per participant
N/A N=382 Aligning Resources to Care for Homeless Veterans
Homeless Persons · Primary Health Care
Primary: A Primary Outcome for This Study is the Number of Non-acute Emergency Department Visits. — 1.1; 0.8; 0.7; 1.0 number of visits
Phase 4 N=36 UW-CTRI Triple Medication Smoking Cessation Study
Smoking
Primary: Number of Participants With Adverse Events — 27; 26; 23; 15 Participants
Phase 4 N=70 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
Healthy
Primary: Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose) — 411.53; 620.36; 522.42; 183.97 h*uM
Phase 2 N=94 A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Diabetes Mellitus, Type 2
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 12; 12; 11 Participants
Phase 3 N=1,231 A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
Chicken-pox Illness (Varicella Virus Disease) · Chickenpox
Primary: Number of Subjects Reporting Fever — 24; 32 Subjects
Phase 2 N=93 A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 — -8.91; -13.11; -8.63; -47.20 percent change — p=0.5661
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…